Revolutionizing Large Molecule Bioprocess Development with Benchling: A Case Study with Gilead Sciences

KB at your finger tips

This is one stop global knowledge base where you can learn about all the products, solutions and support features.

Products-Benchling

Revolutionizing Large Molecule Bioprocess Development with Benchling: A Case Study with Gilead Sciences

Introduction to Gilead Sciences and Benchling Partnership

Gilead Sciences, a renowned biopharmaceutical company dedicated to medical breakthroughs, partnered with Benchling to enhance large molecule bioprocess development. With a focus on novel therapies for life-threatening diseases, Gilead sought to bolster scientist productivity, collaboration, and data insights to elevate efficiency and predictability in their development processes.

Challenges Faced by Gilead Sciences

Gilead encountered challenges due to siloed project data, hindering information flow across teams. Managing multiple systems and databases through disparate tools led to data silos and manual handoffs that bottlenecked processes. Additionally, aggregating data for analysis was time-consuming, impeding data-driven decision-making.

Transformational Outcomes with Benchling Implementation

Implementing Benchling resolved Gilead's data unification issues by creating a centralized platform for improved collaboration. The platform enabled seamless end-to-end sample traceability and data aggregation across different teams. Standardized data capture and an intuitive interface enhanced scientist productivity, allowing for automated status tracking and quick access to analytical results.

Enabling Data-Driven Decision Making

Benchling facilitated clearer insights for Gilead's scientists by simplifying data aggregation and trend analysis. The platform empowered the Biologics team to monitor processes effectively, identifying deviations and progress within workflows. Utilizing Benchling's audit trails and review processes, Gilead could make data-driven decisions to optimize parameters and protocols.

Conclusion: Benchling's Impact on Gilead Sciences

The collaboration between Gilead Sciences and Benchling resulted in substantial improvements, including enhanced data sharing, reduced data capture time, and increased study review efficiency. By leveraging Benchling's capabilities, Gilead advanced its large molecule bioprocess development, setting a new standard for productivity and innovation in the biopharmaceutical industry.

Stay Ahead in Today’s Competitive Market!
Unlock your company’s full potential with a Virtual Delivery Center (VDC). Gain specialized expertise, drive seamless operations, and scale effortlessly for long-term success.

Book A Meeting To Setup A VDC

Optimizing Agritech Research and Development with Benchling

The Importance of Agritech R&D in Revolutionizing Agriculture

Agricultural technology, or agritech, has become a key player in shaping modern farming practices. With the goal of increasing food security, reducing greenhouse gas emissions, and utilizing natural resources efficiently, agritech R&D plays a crucial role in driving innovation within the agricultural industry. To achieve these breakthroughs, research and development teams require sophisticated informatics tools that can integrate data across various domains, including chemistry, genomics, and sample tracking.

Read article

Revolutionizing Antibody and Protein R&D with Benchling Solutions

The Evolution of Antibody R&D

The field of antibodies and proteins is witnessing a transformative era in the fight against critical illnesses like cancer and immune system disorders. Innovations in monoclonal antibody technology, bispecifics, and antibody-drug conjugates are paving the way for more effective treatments with enhanced safety profiles. Antibody research and development (R&D) teams are embracing diverse formats, integrating cutting-edge technologies such as Next-Generation Sequencing (NGS) and CRISPR, and automating key processes to drive the development of groundbreaking antibodies.

Read article

ElevateBio: Revolutionizing Cell and Gene Therapy Research with Benchling's Digital Solutions

Transforming Infrastructure for Optimal CGT Development Processes

Cell and gene therapies (CGTs) are paving the way for advanced disease treatments and personalized medicines, with several already gaining FDA approval. However, one major challenge faced by CGT companies is the inefficiencies in their infrastructure, hindering the development of life-saving therapeutics. ElevateBio recognized these bottlenecks and set out to revolutionize CGT development by leveraging a groundbreaking solution. Through Benchling's integrated technologies model, ElevateBio is empowering the acceleration of design, manufacturing, and development of various genetic medicines. This unique platform offers turnkey scale and biotechnological capabilities, enabling CGT processes and programs to reach their full potential.

Read article

Welcome to Knowledge Base!

KB at your finger tips

Products-Benchling